Published in Br J Cancer on December 15, 2003
Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst (2008) 5.74
Na+/H+ exchanger regulatory factor 1 inhibits platelet-derived growth factor signaling in breast cancer cells. Breast Cancer Res (2008) 1.14
Expression analysis of candidate breast tumour suppressor genes on chromosome 16q. Breast Cancer Res (2005) 0.96
Low-risk susceptibility alleles in 40 human breast cancer cell lines. BMC Cancer (2009) 0.94
Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models. Cancer Gene Ther (2006) 0.92
Analysis of 41 cancer cell lines reveals excessive allelic loss and novel mutations in the SIRT1 gene. Cell Cycle (2012) 0.78
p53 mutations in human cancers. Science (1991) 31.96
Genetic instabilities in human cancers. Nature (1998) 22.76
Allelotype of colorectal carcinomas. Science (1989) 5.54
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J (1995) 4.55
A mutator phenotype in cancer. Cancer Res (2001) 4.41
Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science (1988) 4.15
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res (2000) 3.83
E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene (1996) 3.35
Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res (1995) 3.33
Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science (1988) 2.83
Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice. Cancer J Sci Am (2006) 2.68
Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res (1990) 2.57
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping. Genes Chromosomes Cancer (2000) 2.24
Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res (1997) 2.14
Genetic alterations in breast cancer. Genes Chromosomes Cancer (1995) 1.86
Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. Oncogene (1991) 1.81
Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. Cancer Res (2001) 1.78
Accumulation of genetic alterations and progression of primary breast cancer. Cancer Res (1991) 1.70
At least four different chromosomal regions are involved in loss of heterozygosity in human breast carcinoma. Genomics (1989) 1.55
Comparison of features of human breast cancer cell lines and their corresponding tumors. Clin Cancer Res (1998) 1.51
Molecular cytogenetic analysis of breast cancer cell lines. Br J Cancer (2000) 1.36
Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res (1997) 1.33
A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. Cancer Res (2000) 1.29
A checkpoint on the road to cancer. Nature (1998) 1.24
Mutation rate of MAP2K4/MKK4 in breast carcinoma. Hum Mutat (2002) 1.21
Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res (1994) 1.21
Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res (1996) 1.20
Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res (1995) 1.14
Allelic loss of chromosomal arm 8p in breast cancer progression. Am J Pathol (1998) 1.13
Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res (2000) 1.09
Association between RB-1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival. Int J Cancer (1995) 0.96
Differences in patterns of allelic loss between two common types of adult cancer, breast and colon carcinoma, and Wilms' tumor of childhood. Int J Cancer (1991) 0.92
Frequent allelic loss at the TOC locus on 17q25.1 in primary breast cancers. Genes Chromosomes Cancer (1999) 0.81
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet (1996) 4.09
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res (1995) 3.33
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet (2005) 2.65
Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am (1998) 2.03
Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. Cancer Res (2001) 1.78
Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res (1996) 1.75
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer (2007) 1.58
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology (2009) 1.57
miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene (2012) 1.54
Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer (2004) 1.52
Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012. Euro Surveill (2013) 1.51
Biobanking for interdisciplinary clinical research. Pathobiology (2007) 1.43
Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet (2004) 1.39
C3 proactivator (C3PA) as an acute phase reactant. Clin Exp Immunol (1974) 1.35
Mechanoreceptors in the human anterior cruciate ligament. Anat Rec (1986) 1.32
Dpc4 transcriptional activation and dysfunction in cancer cells. Cancer Res (1998) 1.29
Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol (2010) 1.24
Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells. Mol Carcinog (1999) 1.20
Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol (2005) 1.20
TuBaFrost 2: Standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network. Eur J Cancer (2006) 1.20
Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective study. Clin Genet (2007) 1.16
Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways. Oncogene (2006) 1.15
Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. Cancer Res (1996) 1.14
Role of Mdm4 in drug sensitivity of breast cancer cells. Oncogene (2010) 1.13
The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer (2009) 1.13
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat (2011) 1.12
17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia (2008) 1.05
TuBaFrost 3: regulatory and ethical issues on the exchange of residual tissue for research across Europe. Eur J Cancer (2006) 1.01
Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). Eur J Cancer (2006) 0.98
Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat (2010) 0.98
Genomic sequencing of DPC4 in the analysis of familial pancreatic carcinoma. Diagn Mol Pathol (1997) 0.98
Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies. Appl Immunohistochem Mol Morphol (2000) 0.97
DPC4 gene mutation in colitis associated neoplasia. Gut (1997) 0.96
Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing. Ann Oncol (2006) 0.96
A modified gold chloride method for the demonstration of nerve endings in frozen sections. Stain Technol (1985) 0.95
Genetic analyses of apparently sporadic pheochromocytomas: the Rotterdam experience. Ann N Y Acad Sci (2006) 0.95
Pitfalls in molecular analysis for mismatch repair deficiency in a family with biallelic pms2 germline mutations. Clin Genet (2011) 0.93
Effects of anesthesia, surgery and inflammation upon host defense mechanisms. I. Effects upon the complement system. Int Arch Allergy Appl Immunol (1975) 0.92
Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats. Br J Cancer (2010) 0.92
Impact of screening for breast cancer in high-risk women on health-related quality of life. Br J Cancer (2004) 0.92
Microsatellite instability in a pleomorphic rhabdomyosarcoma in a patient with hereditary non-polyposis colorectal cancer. Histopathology (2003) 0.92
TuBaFrost 1: Uniting local frozen tumour banks into a European network: an overview. Eur J Cancer (2006) 0.91
A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting. Gut (2008) 0.91
Genetic testing in hereditary non-polyposis colorectal cancer families with a MSH2, MLH1, or MSH6 mutation. J Med Genet (2002) 0.91
The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy. Eur J Cancer (2006) 0.91
High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas. Cytogenet Genome Res (2007) 0.89
Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease. Br J Cancer (2003) 0.89
Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res (1998) 0.88
Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. Breast Cancer Res Treat (2006) 0.87
N-Benzyl-isatin. Acta Crystallogr Sect E Struct Rep Online (2012) 0.87
Luteinizing hormone signaling and breast cancer: polymorphisms and age of onset. J Clin Endocrinol Metab (2003) 0.86
Association between the CHEK2*1100delC germ line mutation and estrogen receptor status. Int J Gynecol Cancer (2006) 0.86
TuBaFrost 5: multifunctional central database application for a European tumor bank. Eur J Cancer (2006) 0.85
Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation. Eur J Surg Oncol (2002) 0.84
Passive coping and psychological distress in women adhering to regular breast cancer surveillance. Psychooncology (2007) 0.84
Serum proteomic patterns for ovarian cancer monitoring. Int J Gynecol Cancer (2007) 0.83
Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy? Ann Oncol (2007) 0.82
Molecular dissection of the chromosome band 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin-dependent kinase 6 at both genomic and protein expression levels. Genes Chromosomes Cancer (2008) 0.82
PTEN in colorectal cancer: a report on two Cowden syndrome patients. Clin Genet (2011) 0.82
Therapeutic mild hypothermia improves outcome after out-of-hospital cardiac arrest. Neth Heart J (2009) 0.82
Virtual microscopy in virtual tumor banking. Adv Exp Med Biol (2006) 0.80
Possible consequences of applying guidelines to healthy women with a family history of breast cancer. Eur J Hum Genet (2003) 0.80
Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma. Dis Esophagus (2014) 0.79
Morphology of testicular parenchyma adjacent to germ cell tumours. An interim report. APMIS (2003) 0.79
Malignant mesenchymoma of the uterus, arising in a leiomyoma. Histopathology (2002) 0.79
Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy. Anticancer Drugs (2004) 0.79
TuBaFrost: European virtual tumor tissue banking. Adv Exp Med Biol (2006) 0.78
TuBaFrost 6: virtual microscopy in virtual tumour banking. Eur J Cancer (2006) 0.78
Molecular parameters associated with insulinoma progression: chromosomal instability versus p53 and CK19 status. Cytogenet Genome Res (2006) 0.78
Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. Eur J Cancer (2005) 0.77
The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis. Br J Cancer (2004) 0.77
PTEN gene loss, but not mutation, in benign and malignant phaeochromocytomas. J Pathol (2006) 0.77
9B.09: IDENTIFICATION OF MARKERS PREDICTIVE FOR MALIGNANT BEHAVIOR OF PHEOCHROMOCYTOMAS AND PARAGANGLIOMAS. J Hypertens (2015) 0.77
Functional analysis of novel androgen receptor mutations in a unique cohort of Indonesian patients with a disorder of sex development. Sex Dev (2009) 0.77
Absence of TERT promoter mutations in esophageal adenocarcinoma. Int J Cancer (2014) 0.76
Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear beta-catenin expression. Br J Cancer (2004) 0.76
Effect of memantine on the alpha 7 neuronal nicotinic receptors, synaptophysin- and low molecular weight MAP-2 levels in the brain of transgenic mice over-expressing human acetylcholinesterase. J Neural Transm (Vienna) (2004) 0.76
Translational research on esophageal adenocarcinoma: from cell line to clinic. Dis Esophagus (2013) 0.76
CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Res Treat (2013) 0.76
[Preventive surgical prcedures for inherited risk of breast cancer]. Ned Tijdschr Geneeskd (2005) 0.76
Quality control in diagnostic molecular pathology in the Netherlands; proficiency testing for patient identification in tissue samples. J Clin Pathol (2004) 0.75
2-Ethyl-3-hy-droxy-1-isopropyl-4-pyridone. Acta Crystallogr Sect E Struct Rep Online (2012) 0.75
TuBaFrost 4: access rules and incentives for a European tumour bank. Eur J Cancer (2006) 0.75
SALVAGE OF UNUNITED FEMORAL NECK FRACTURES: Colonna Reconstruction. Orthopedics (1981) 0.75
A vascular Necrosis Following Closed Treatment of CDH: A Case Report of the Long Term Sequelae. Orthopedics (1983) 0.75
Gene expression profiling of treatment resistance: hype or hope for therapeutic target identification. Int J Gynecol Cancer (2006) 0.75
Biochemical analysis and subcellular distribution of E-cadherin-catenin in adenocarcinomas of the gastro-oesophageal junction. Anticancer Res (2004) 0.75
Symptom perception: psychological correlates of symptom reporting and illness behavior of women with medically unexplained gynecological symptoms. J Psychosom Obstet Gynaecol (1994) 0.75
Cardiac myxoma with atypical glandular component, report of a case. Histopathology (2006) 0.75
[Adverse effects of antihistaminics]. Z Hautkr (1988) 0.75